Replies to post #81233 on Biotech Values

[bladerunner1717]

So, Dew, what would be your guess on upfronts, if NVS decides to license IDX184?


Bladerunner

[DewDiligence]

Up-Front Payments of HCV Partnerships

[Added entry for Telaprevir in Asia, although this is technically a
monetization of a prior agreement This list does not purport to be
complete. Items are listed in descending order of up-front amount.]

 
                                    Up-front 
 Licensor Licensee Product    Phase Cash($M) Date iHub reference 
 VRTX     JNJ      Telaprevir   2     165*   6/06 #msg-11830934 
 VRTX     Mitsbshi Telaprevir   3     105†   7/09 #msg-40126798 
 ZGEN     BMY      IFN-Lambda   1     105    1/09 #msg-34768182 
 IDIX     NVS      NM283        2     100‡   3/06 #msg-10407463 
 ITMN     Roche    ITMN-191    p.c.    60   10/06 #msg-14356850 
 HGSI     NVS      Albuferon    2      45    6/06 #msg-11451787 
 ANDS     NVS      ANA975       1      20    2/05 #msg-6545305 
 LG Ltd   GILD     LB84451      2      20   11/07 #msg-24337514 
 Genelabs GSK      n/a         p.c.    12.5  5/06 #msg-11431616 
 Medivir  JNJ      TMC435      p.c.    10   11/04 n/a 
 Benitec  PFE      TT-033      p.c.    n/a   1/08 #msg-25817504 
  
 *For rights in Europe, South America, Australia, and the Middle East. 
 †For rights in Japan/Asia; monetization of amended 2004 agreement. 
 ‡Includes $75M NVS paid for rights to NM283 and telbivudine in 2003.